statistical methods that have been devised (Zuhrie (1978) presented trends with time in estimated median survival at the last MRC Leukaemia Review meeting) for the analysis of survivorship in the series of studies from which the above example was drawn. I am concerned that correct statistical methodology should be applied to these data, as they probably represent the largest immunotherapy study at any one British hospital.
When analysing survival data from clinical trials, it is usually unwise to depart from the standard statistical methods of logrank Pvalues and Kaplan-Meier life-tables (as described, for example, in Br. J. Cancer (1977) 35, 1) unless expert statistical guidance is available to avoid misleading inferences being drawn. The accepted definition of the "logrank" and "life- SIR.-We have read Mr Peto's letter and his earlier comments on the manuscript of our paper (Harris etal. (1978) Br.J. Cancer, 37, 282), which had led to its extensive revision. Logrank analysis as recommended by Peto et al. (1977) (Br. J. Cancer, 35, 1) has been used throughout the paper, and also for the data used in the lecture given by one of us (SRZ) at the 1978 MRC Leukaemia Review meeting. Mr Peto's objections are to our additional analyses, notably of relapse-todeath times in Manchester Trial 2. These were acknowledged in our paper, and the data were made available in full in the appendix.
In view of Mr Peto's comments, it is worth reiterating our reasons for analysing "relapse-to-death" separately, even though statistical opinions are divided. Essentially, this eliminated from the analysis those patients whose atypically long survival might be due largely to factors other than treatment. We (Freeman et al. (1973) Harris et al., (1978) Br. Med. Bull. in press) have observed that in patients with AML the probability of entering remission and of prolonged survival are associated with HLAtype. Consequently, the "tails" or plateaux of AML survival curves include an excess of patients with resistance genes related to HLA. AML patients at the onset of their disease thus make up a heterogeneous population, some sub-sets of which are more likely to become long survivors than others. These observations expose the fundamental fallacies of randomized trials of indifferent treatment protocols for rare fatal diseases like AML. Inevitably, small numbers mean that each treatment arm will contain different proportions of patients with inherently good or bad prognosis in relation to the form of treatment that they receive. Genetically determined differences in patients' resistance may greatly exceed the minor differences to be expected from poor treatment protocols. The 
